A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.
NCT ID: NCT06889753
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-10-29
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What is the difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex Water Soluble Pollen Extract (WSPE), Lipid Soluble Pollen Extract (LSPE), and Placebo?
Participants will be asked to complete the MRS assessment tool to rate their menopausal symptoms while receiving either WSPE, LSPE, or Placebo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
NCT06186531
Black Cohosh Extract for Treatment of Moderate to Severe Menopausal Symptoms
NCT02093650
A Pooled Analysis of the Data From Two Studies of Ammonium Succinate for Menopausal Symptoms
NCT03043690
Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms
NCT06787443
12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being.
NCT07242430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Graminex Water Soluble Pollen Extract (WSPE)
Graminex WSPE is a water soluble extract from flower pollen standardized to 6% amino acids.
Graminex WSPE
Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.
Graminex Lipid Soluble Pollen Extract (LSPE)
Graminex LSPE is a lipid soluble pollen extract standardized to 7% phytosterols.
Graminex LSPE
Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Graminex WSPE
Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.
Graminex LSPE
Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive
3. Self-reported menopausal women who have not had a menstrual period for \>12 months prior to screening and are experiencing at least moderate menopausal symptoms as assessed by the total MRS score of ≥9 at screening
4. Presence of menopausal symptoms for at least six months prior to screening including, vasomotor symptoms (hot flushes, sweating) AND at least two of the following symptoms: sleep disturbance, joint pain, mood changes, fatigue and lack of energy, vaginal dryness, urinary changes, and changes in sexual function
5. Agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, medications, dietary supplements, and sleep
6. Able and willing to complete all study assessments
7. Provided voluntary, written, informed consent to participate in the study
8. Healthy as determined by medical history with no unstable, diagnosed medical conditions as assessed by the Qualified Investigator (QI)
Exclusion Criteria
2. Allergy (including bee products or pollen, sensitivity, or intolerance to investigational products or placebo ingredients
3. Ongoing diagnosis with anxiety disorder, sleep disorder, or major depression as assessed by the QI
4. Ongoing unstable diagnosis of musculoskeletal disorders as assessed by the QI
5. Current untreated urogenital diagnosis as assessed by the QI
6. Unstable metabolic disease or chronic diseases as assessed by the QI
7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
9. Current unstable Type I or Type II diabetes
10. Significant cardiovascular event in the past six months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least three months will be considered by the QI
13. Major surgery in the past three months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years
15. after diagnosis are acceptable
16. Individuals with unstable autoimmune disease or are immune compromised as assessed by the QI
17. Use of medical cannabinoid products
18. Chronic use of cannabinoid products (\>2 times/week) as assessed by the QI
19. Alcohol intake average of \>2 standard drinks per day as assessed by the QI
20. Alcohol or drug abuse within the last 12 months
21. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
22. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
23. Individuals who are unable to give informed consent
24. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
25. Asthmatic, as assessed by the QI
45 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KGK Science Inc.
INDUSTRY
Graminex LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Crowley, MD
Role: PRINCIPAL_INVESTIGATOR
KGK Science Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KGK Science Inc.
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24GXCFG01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.